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Abstract
Severe sepsis and septic shock are major causes of morbidity and mortality in
intensive care units worldwide, accounting for 250,000 deaths each year in the United
States alone. Sepsis is the clinical manifestation of a dysregulated innate immune
response to microbial infection. Over-activation of inflammatory mediators may result in
multiple organ failure, acute circulatory failure, and death. Recognition of non-self
microbial products by host cell receptors is fundamental to the innate inflammatory
response. CD14 is a general pattern recognition receptor that is responsible for sensitive
detection of many unique pathogen-associated toxins such as LPS, PGN, and LTA. The
structure and function of CD14 has extensive implications in understanding the innate
immune response and progression of the potentially fatal syndrome sepsis. However, no
structural data of CD14 has been acquired; the nature of its interactions with endotoxins
has yet to be characterized. Production of milligram quantities of protein is necessary for
NMR structural studies of CD14. This paper discusses the endotoxin-induced innate
response, treatment strategies for sepsis, and gives a protocol for the expression and
purification of a 152 amino acid fragment of soluble CD14.

Background
Sepsis
Sepsis is a condition involving an out of control host systematic inflammatory
response caused by the infection of pathogenic micro-organisms in humans. As the
condition progresses, it can lead to multiple organ dysfunction 'severe sepsis', and even
to a state of acute circulatory failure characterized by arterial hypotension 'septic shock'
and death (Levy et a\., 2003). Sepsis is the tenth most common cause of death in the
United States-affecting approximately 750,000 patients annually and accounting for
over 210,000 deaths per year (Hoyert et a!., 2001; Angus et aI., 2001). With the incidence
of sepsis rising at rates between 1.5-8% per year despite technical improvements made
in intensive care units (ICUs), and costs of approximately $16.7 billion per year
burdening the US health care system, massive research efforts have been undertaken in
search of improved treatments and therapy(Martin et aI., 2003).
It is the innate immune response that is the first line of defense when a pathogen
crosses the host's natural defense barriers, however, it is the over-activation of the innate
immune system that is directly responsible for the deleterious symptoms of sepsis.
Leukocytes play an important role, recognizing the pathogens and eliciting inflammatory
initiators. The release of proinflammatory mediators, such as chemokines and cytokines
facilitates the migration of serum-soluble components out of the vasculature and into the
specific area where the microbial invasion has been detected (Glauser et a!., 1991;
Mirlashari & Lyberg, 2003; Dentener et aI., 1993). This response is essential for effective
combat of host microbial infection.
In septic shock, the endotoxin-induced over-synthesis of pro-inflamatory
cytokines and chemokines, IL-l, IL-6, IL-8, IL-12, and TNF-a, and over-activation of
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macrophages results in the release of toxic molecules from polymorphonuclear celJs.
These processes trigger the further production of cytokines and endothelial necrosis,
resulting in coagulatory responses and multiple complex proteolytic cascades
(Riedemann et aI., 2003). This self-amplifying and dysregulated inflammatroy response
often leads to organ failure and mortality, if not curtailed by counter-regulatory systems
and anti-inflammatory cytokines (Baumgartner & Calandra, 1999).

Endotoxins LPS & PGN
There are several components associated with pathogens that the immune defense
system engages for detection and initiation of inflammatory response. Of the bacterial
components commonly exploited by the immune system are lipopolysaccharide (LPS),
peptidoglycan (PGN), lipotechoic acid (LTA), lipoarabinomannan (LAM), lipoprotein
and unmethylated DNA with CpG motif. LPS is present in large quantities on the surface
of Gram-negative bacteria, while PGN and LTA are important components of Grampositive bacteria, though all three reside at low levels on the outer surfaces of both types
of cells.
Although other bacterial components are recognized by the innate immune
response system, LPS and PGN form the two major bacterial endotoxin components
recognized by innate defenses. The outer protectant on the membrane of Gram-negative
bacteria is constituted, in large part, of the phosphoglycolipid LPS (Joiner, 1988). The
lipid A moiety of LPS (Fig . 1) is highly hydrophopic and tethers one end of the endotoxin
within the phospholipid bilayer allowing the O-region of LPS to form a perimeter of
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defense on the extracellular surface, thwarting the actions of bile salts and hydrophobic
antibiotics (Backhed, 2003).
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surround the membrane in bacteria and are responsible
for maintaining the cel1ular shape and withstanding
the force created by the osmotic gradient of the
bacteria and the surrounding environment. LPS and
PGN are necessary for bacterial vitality and are released
during cell growth and death.
Figure 1. Molecular motifs recognized by
CD14: Lipid A Moiety of LPS &
PGN repeating units.

CD14 Human Endotoxin Receptor

The human endotoxin receptor CD14 is in the vanguard of the host innate
immune defenses. Responsible for detection of endotoxins at subnanomolar
concentrations, CD14 is a pattern recognition receptor that detects unique pathogenassociated molecular motifs (Wright et aI., 1990). The 55 kDa
glycosyJphosphatidyJinositol (OPI)-anchored protein is expressed on the membranesurfaces of monocytes and macrophages and is critical for early mobilization of innate
defenses and activation of anti-microbial pathways (Haziot et al. 1998; Lee et aI., 1992;
Weidemann et aI., 1994). CD14 is also expressed as a soluble form (sCD14) lacking the
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GPI anchor at concentrations of 2-6 Il-g/ml in human serum. Soluble CD14 acts to
reconnoiter and activate responses to endotoxin in endothelial, epithelial, and other cells
devoid of the membrane-bound form (mCD14) (Grunwald et aI., 1992; Pugin et aI., 1993;
Frey et aI., 1992). Although microorganisms have tremendous variety, LPS and PGN are
evolutionarily conserved and not expressed in higher eukaryotes, and as such, are ideal
candidates for pattern recognition . Their distinct molecular-motifs provide a mechanism
for highly-sensitive recognition by the pattern recognition receptor CD14. This allows the
innate immune system to subdue and eliminate most infections quickly.
CD14 plays an important role in the initiation of sepsis. Previous studies have
revealed attenuation of the systematic response during sepsis by blocking CD14, and it
has been inferred that the primary role of CD14 is to enhance the sensitivity of the
endotoxin-induced signal for cel1ular activation. A precise molecular-level understanding
of the CD14-endotoxin interactions is necessary to understand the pathogenesis of sepsis.

LPS & PGN Induced Signal Transduction
LPS and PGN induced intracellular signaling as part of the innate immune
response is initiated by binding of CD14 to these endotoxins. CD14, however, lacks a
transmembrane domain and is incapable of directly mediating the activation of signaling
pathways within the cell. Instead, it associates with and presents the endotoxin to Tolllike receptor (TLR), activating the ensuing intracellular signaling cascade. The Toll-like
receptor family has 17 known members and consists of an extracellular leucine rich
repeat (LRR) domain and a cytoplasmic TolllIL-lR (TIR) homology domain (Takeuchi
& Akira, 2001). LRRs are short protein chains of 20 to 29 amjno acids found in a diverse
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group of proteins that includes CD14 and myeloid differentiation protein 88 (MyD88).
Due to the evolutionary conservation of LRR's in major pattern recognition proteins and
receptors, the LRR is putatively thought to be important in the interaction of complexed
CD14, TLR-4, and MyD88 (Kobe & Kajava, 2001).
Upon endotoxin recognition by CD14, a legion of
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Figure 2. CD14 mediated intracellul ar signaling
cascade in response to end otox in detection.

primarily interacts with TLR-4 (Shimazu et
aI. , 1999), though some studies suggest that

TLR-2 may playa role in LPS induced signaling as well(Yang et a!., 1998; Kirschning et
aI., 1998). Although studies have shown that TLR-2 alone can activate the PON signaling
cascade, heterodimers between TLR-2:TLR-1 or TLR-2:TLR-6 have also been suggested
to associate with the PGN-CD14 complex (Ozinsky et aI., 2000).
Though LPS and PON are both recognized by CD14, they stimulate different
TLRs, TLR-4 and TLR-2 respectively (Wang et aI. , 2001). However, both TLR-4 and
TLR-2 have similar signaling paradigms upon CD14 mediated activation. Though only
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two requisite proteins have been linked with PGN activation of TLR-2, at least four
proteins are necessary for the optimal cellular response to LPS: CDI4, LPS binding
protein (LBP), Toll-like receptor 4 (TLR-4), and NID-2. The receptor cluster picture may
not be so simple, however. Recently it was shown that TLR-4 when stimulated with LPS
associates with a complex of receptors involving heat-shock proteins (hsp) 70 and 90,
chemokine receptor 4 (CXCR4), and growth differentiation factor S (GDFS) (Triantafilou
et aL, 2001; Triantafilou et aL, 2002). Additionally, MyD88 associates with TLR-4 and
contributes responsiveness to LPS in some cells (Andreakos et aL, 2003).
MD-2 is a secreted protein that interacts with the extracellular domain of TLR-4.
The function of MD-2 has yet to be fully resolved. It has been suggested that MD-2
induces a conformational change in TLR-4 necessary for the transport of the nascent
protein from the endoplasmic reticulum to the cellular membrane (Nagai et al., 2002). A
more plausible explanation is that MD-2 functions to improve TLR-4 binding sensitivity
to LPS (Akashi et aL, 2000; da Silva Correia et aL, 2001). Two domains responsible for
TLR-4 binding and LPS responsiveness have been identified on MD-2 by site-directed
mutagenesis (Re & Strominger, 2003; Mancek et aL, 2002). The domain shown to
increase LPS sensitivity is rich in aromatic and basic amino acids thought to interact with
the negati veJy charged and hydrophobic regions of LPS (Re & Strominger, 2003).
Upon LPS-induced activation ofTLR-4, the signal is transduced by
phosphorylation of various adaptor proteins such as Myd88, IL-l receptor-associated
kinase (IRAK), and tumor necrosis factor-associated factor-6 (TRAF6) (Guillot et aL,
2003). A cascade of intracellular signaling ensues that in tum activates mitogen-activated
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protein kinases (MAPKs), NF-KE-inducing kinase (NIK), and IKE kinase (IKK)
(Hoffmann, 2002). Upon stimulation of IKK, IKE is phosphorylated and degraded.
NF-KE is an inducible transcription factor that is constitutivly expressed in most
cells. However, in cells at rest it is sequestered to the cytoplasm because it is associated
with IKE. IKE signals for active transport out of the nucleus (Woronicz et aI., 1997). Only
after IKE has been phosphorylated, ubiquitinated, and degraded is NF-KE active and able
to effectively migrate to the nucleus (May et aI., 2002). NF-KE activation and migration
into the nucleus results in the promotion of a cavalry of self-amplifying proinflammatory
cytokines-IL-l, IL-4, IL-8, and TNF-a (Kopp & Medzhitov, 1999). Their release at the
site of microbial invasion is the first step in the innate host response. This sophisticated
innate armament allows for early detection and general defense against invading
pathogens.

Strategies for Treatment of Sepsis Involving CD14
Previous treatment strategies in ICUs have involved the use of agents that block
the activities of pro-inflammatory mediators, but have had limited success at decreasing
the morbidity of patients (Glauser, 2000). In fact, clinical trials over the past 40 years
including administration of polyclonal human antiserum against LPS, monoclonal
antibodies against lipid A and TNF-a, and anti-coagulatory molecules have all failed to
produce substantial improvements in patient mortality rates (Riedemann et aI., 2003).
The new frontier of treatment strategies involves the design of antagonistic
molecules that compete with microbial endotoxins by interacting with pattern recognition
receptors, and the delineation of high-affinity compounds that bind endotoxins and
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repress their ability to elicit an innate response. Potential targets include LBP, CDI4,
TLR-2, TLR-4, TLR-6, and MO-2. It is important, however, that complete inactivation of
proteins pivotal to innate immunity be avoided.
CD14 may be an ideal candidate for treatment, as it confers sensitivity to several
transmembrane signaling molecules. Currently, monoclonal antibodies against CD14 are
being evaluated in phase II studies (Bochud & Calandra, 2003). CD 14-deficient mice
were found to be highly resistant to shock induced by either live Gram-negative bacteria
or LPS, while transgenic mice expressing human CD14 showed increased susceptibility
to endotoxic shock and hypersensitivity to LPS (Haziot et aI., 1996; Ferrero et ai., 1993).
Clinically blocking CD14 activity in cases of sepsis may represent a therapy that
remedies the dysregulated inflammatory response without disrupting the overall ability of
the innate immune system to fight the infection. However, without any structural data on
the protein, rational drug design for this purpose is impossible.
152

No X-Ray or NMR structural studies on
CD14 have been conducted so far and the tertiary

Endotoxin Binding
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structure, essential for understanding the binding of
Amino acid sequence of CD14

CD14 to LPS and PGN, is not yet known. Further,
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no structure of a protein homologous CD14 exists
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either, preventing homology modeling.
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LSDNPGLGER GLMAALCPHK FPAIQNLALR NTGMETPTGV CAALAAAGVQ

LRR region
PHSLDLSHNS LRATVNPSAP RCMWSSALNS LNLSFAGLEQ VPKGLPAKLR

Mutagenesis and limited proteolysis studies have
identified two regions on CD 14 thought to be
responsible for binding LPS: residues 39-44

VLDLSCNRLN RAPQPDELPE VDNLTLDGNP FLVPGTALPH EGSMNSGVVP
ACARSTLSVG VSGTLVLLQG ARGFA
GPI anchor sequence

Figure 3. CD14 sequence and motif diagram. The
endotoxin binding domain was expressed and
purified.

(Stelter et aI., 1997) and residues 57-64
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(McGinley et al., 1995). Efforts to crystallize CD14 have been largely unsuccessful.
NMR spectroscopy is an alternative method for structure determination. However,
milligram quantities of CD14 are needed for NMR experiments. An efficient expression
and purification protocol is necessary to obtain these amounts of protein and that too in
isotopically labeled forms required for NMR structural studies.

Materials & Methods
CD14 20-171 Vector & Transformation into BL21-GoLd
The coding sequence for CD14 from amino acids 20-171 was codon
optimized for expression in E. coLi and synthesized (Bio ST). The resulting sequence was
inserted into a pET30a vector (Novagen) between Xho I and Nde I restriction
endonuclease sites such that only the C-terminal end would have the 6X-his tag. The Nterminal His6 tag was not included because of its proximity to the functionally active
portion of the protein. The pET30a plasmid confers kanamycin resistance to transformed
cells for which it is compatible and contains an upstream lac operator for controlled
induction of protein synthesis with IPTG.
BL21-Gold(DE3) pLysS competent, chloramphenicol resistant cells from
Stratagene were transformed after thawing on ice for 15 min. 3 J.ll, approximately 200 ng
of plasmid DNA, was added to 35 J.ll of cells. After 10 minutes on ice, the solution was
submitted to heat shock for 90 seconds at 42° C and then added to 35 J.ll of LB broth in a
sterile Eppendorf tube. After incubation for 30 minutes at 37° C and 200 RPM, 35 J.ll
were spread onto LB-Agar plates containing kanamycin and chloramphenicol to select
transformed cells only, and incubated inverted at 37° C overnight. Single colonies were
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picked for all growths. The BL21-Gold(DE3) pLysS strain of E. coli was selected
because it encodes T7 Iysozome, a T7 RNA polymerase inhibitor.

In order to ensure the purity of the vector DNA and reduce the frequency of
nicked copies for optimal expression, the CD14 vector transformed BL21 cells were
grown in 50 ml of LB broth for approximately 4

'12

hours, OD 600 of .1-.2, and plasmid

DNA was purified using a QIAprep Miniprep kit from Qiagen. To measure purity of the
miniprep vector DNA, the absorbance was measured at 260 and 280 nm, and 2601280
ratios between 1.6 and 1.8 were accepted as pure.

Expression of soluble CD14 20-171
For growth of transformed cells, 25g of LB, Miller powder from Fisher was
dissolved per liter of distilled/deionized water. The solution was autoclaved for 25
minutes, and cooled to room temperature before innoculation. Colonies from plates
prepared as described above were transferred using sterile loops to 50 ml of flasks
containing LB broth with kanamycin and chloramphenicol at concentrations of 50 and 35
Ilg/ml, respectively. The cells were grown at 3T C with agitation of 200 rpm. Once the
cells entered the log phase of growth, OD 6oo of .3, they were transferred to larger shaker
flasks. The cells were then grown to an OD 600 of .6 before induction with 5 mM IPTG.
After 3-4 hours, the cells were harvested by centrifugation at 6000 rpm for 15 minutes,
and stored at -80 0 C until purification. Typical yields were 3-5 grams per liter of cells
containing CD14 20-171 in the form of inclusion bodies which required resolubilzation.
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Optimization of Resolubilization, Refolding & Purification of CD 14 20-171
The frozen cells were resuspended in 50 mM Tris buffer pH 8.0 and stirred at 4°
C for one hour. A cocktail protease inhibitor tablet (Roche) was added to prevent protein
cleavage. In order to lyse the cells, the solution was sonicated for five 30 second bursts
using a Branson Sonifier 450.
PBS containing 6 M urea was originally used to resolubilize the CD14 20-171
inclusion bodies. This refolding buffer when added to the lysate formed a highly viscous
solution that hindered purification. Dilution of the solution 8 fold after the addition of
urea did not resolve the problem. The solution remained viscous and clogged the Ni-NTA
SuperfJow column (Qiagen) used for the purification of His6 tagged proteins. As a means
of reducing the viscosity, a preliminary purification step was added to the protocol.
Gravity columns were packed with anion-exchanging Sepharose 6B (Sigma-Aldrich).
Although, flow-rates were initially higher, these columns eventually became congested as
well. The loaded solution was then eluted with stepwise increments of increasing KCI
concentration. The fractions of elutant containing CD14 were then successfully loaded
onto the Ni-NTA column (Qiagen), however only small quantities of CD14 were purified
in this fashion.
As an alternative, the viscous 6M urea lysate solution was subjected to
ultracentrifugation at 50,000g. This cleared the lysate considerably and was followed by
passing the supernatant through .44 ~m Stericup filters (Millipore). After
ultracentrifugation and filtration, the cleared lysate passed easily over Ni-NTA columns.
This purification method effectively produces CD14 20-171, however it is taxing and
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requires the use of several Stericup filters. An effective alternative in which
resolubilation by addition of 6 M GuHCI is described below.
For resolubilization of inclusion bodies, guanidine hydrochloride was added to the
lysed cell suspension to make it 60% by weight, and the solution was stirred at 4° C for

1/2

hour. Afterwards, the solution was centrifuged for 30 minutes at 12,000 rpm. The
supernatant was then diluted 6 fold in refolding buffer (50mM Tris pH 8, 2M glycine,
5mM cysteine) and stirred over-night. The solution containing the solubilized and
refolded CD14 20-171 was then centrifuged for 30 minutes at 12,000 rpm to remove any
precipitated debris. Ammonium sulfate precipitation was then performed at 60% by
weight to further purify the protein, and the resulting pellet was dissolved in phosphate
buffer saline (PBS), pH 8.
Gravity flow columns packed with Ni-NTA Superflow from Qiagen were then
loaded with the CD14 solution and washed with 100 ml PBS followed by 50 ml of PBS,
25 mM imidazole. The bound CD14 was eluted with PBS containing 250 mM imidazole,
and the elutant was concentrated in amicon Centripreps (MWCO 10,000) from Millipore
to a volume less than 1m!'

Gels and Western Blotting
PhastGel Homogenous 20% gels from Amersham Biosciences were used to run
purified samples of CD14 20-171. The gels were silver-stained and developed with
formaldehyde. Prior to running the samples, they were boiled for 10 minutes in SDS and
~-ME.

The BioRad Precision Plus Protein Dual Color ladder was used to consistently

mark the CD 14 peak.

13

Western blots were perfonned after boiling the samples in a denaturing, nonreducing buffer containing SDS. Novex pre-cast gels, 18% Tris-Glycine from Invitrogen
were used. 15111 of SDS-boiled sample solution were loaded per well, and gels were run
at 125V for 11/2 hours in an Xcell SureLock Mini-Cell electrophoresis unit from
Invitrogen. After seperation, an Xcell II Blot Module was used to transfer the protein to a
PVDF membrane at 25V for 1Y2 hours. A Tris based solution containing 5% milk, .1 %
Tween was used to block the membrane. Membranes were blocked overnight at 4° with
slow agitation. Primary and secondary antibodies were added and incubated for 1 hour at
room temperature each. Mouse monoclonal human anti-CDl4 (ab8103) from Novus was
diluted 1:400 and used as the primary antibody for CD 14 detection with an HRP
conjugated anti-mouse polyclonal secondary. Additionally, HRP conjugated mouse
monoclonal His6 (ab7857) from Novus was diluted 1:4,000 and used to detennine that
the entire protein and His6 tag had been expressed. CNIDAB precipitating substrates
from Pierce were used to develop the bound HRP conjugated antibodies.

Results & Discussion
Analysis of the primary structure of CD14 shows that the carboxy tenninal
end of CD14 consists of 10 leucine rich repeats (Fig 3), of which 7 leucine rich repeats
are predicted to be involved in interactions with TLRs and other signaling molecules .
Additionally, the first 19 amino terminal residues are a signal peptide that is cleaved
before the protein leaves the endoplasmic reticulum. The functional region of the protein
that recognizes and binds endotoxins is located within the first 152 N-tenninal amino
acids after the signal peptide region. Therefore, for ligand binding and structural studies
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of CD14, residues 20-171 would be appropriate for expression. Shorter fragments of Nterminal CD14 would be subject to protease degradation and were therefore not
considered. E. coli was chosen as an expression system
for CD14 since the use of mammalian cells is unlikely
to generate sufficient quantities of CD 14 for NMR
based structural studies. Expression of CD14 in yeast
has been characterized, however, protein glycosylation
occurs which presents a problem for NMR studies due
to the presence of multiple conformations as a result of
glycosylation.

Figure 4. SDS-Page analysis of
partially purified CD 14. Arrows show
the CDI4 band

CD14 20-171 expression in E. coli using the pET30a expression system was
successful. Yields of CD14 were improved when cultures were inducted at an OD 600 of
.6. When grown to higher concentrations before induction, the yield of cells was greater,
but less total protein was produced. Figure 4 shows that CD14 20-171 migrated with the
20 kDa marker in the PhastGels confirming expression of protein with correct molecular
weight. Expression using the protocol described here results in production of about 1-2
mg of protein/liter of medium. Western blotting results show that anti-human CD14
monoclonal antibody (Novus-ab8103) does bind to N-terminal residues 20-171 when
transferred to PVDF membrane from SDS, non-denaturing gels (Fig 5). It has been
reported that some CD14 antibodies do not recognize CD14 when ran in SDS-PAGE
conditions (Majerle et aI., 1999).
Our recombinant CD14 contains 4 Cysteine residues, and their redox state must
be controlled for proper refolding. This is effectively accomplished by the addition of 5
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mM cysteine to the refolding buffer. Resolubilization of inclusion bodies by addition of

urea is cumbersome and presents many problems associated with the high viscosity of the
solution. Guanidine hydrochloride is an effective alternative for resolubilizing the
protein. The ammonium sulfate precipitation is an essential step that contributes greatly
to the purification protocol. After dissolving the precipitated protein, the CD14 solution is
clear and roughly 50% pure. The CD14 sample purity is increased to approximately 70%
following elution from the Ni-NTA column. To achieve the greater than 95% purity
necessary for acquiring NMR spectra with a high signal to noise ratio, the sample will be
run on a molecular size exclusion column.
Although studies indicate that endotoxin binding takes place between residues 3964 (Stelter et aI., 1997; McGinley et aI.,

,
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1995; Juan et aI., 1995), attempts at
expressing fragments of CD14 much
shorter than 152 residues have been
unsuccessful (Majerle et aI., 2000).
Shorter fragments may not form a

CDI4

CDI4

compact domain and be rapidly

A
degraded upon translation. Therefore,
for ligand binding studies of CD14,
residues 20-171 were chosen . Bacterial

B

Figure 5. Western blots confirming CD14 expression
by using a-CD 14 10 (A) and translation of entire
protein and His6-tag by using a-His6 10 (B). Lanes
1 & 2 in each blot are from preps induced at OD of .6;
Lane 3 was induced at OD 1.2.

expression of CD14 is quick and scaleable, however, one caveat is that many strains of
bacteria possess LPS , a natural ligand of CD14, and care must be taken not to
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contaminate the sample of purified protein. This problem is avoided in part by expressing
the CD14 in inclusion bodies.
Not only does bacterial expression of CD14 produce milligram quantities of
protein required for structural studies in NMR, but the protocols used for unlabeled
expression are easily applied to isotopic labeling of the protein. E. coli BL21 cells grow
and express well in minimal media which allows for unproblematic

13 C

and lSN

incorporation into the protein backbone and sidechains, which is necessary for high
resolution of NMR spectra.
As the progression of sepsis is intimately linked with the induction of several
endotoxin-activated signaling cascades, describing its pathogenesis is exceedingly
complex. CD14 is an ideal candidate for therapy designed to suppress the progression of
sepsis because it confers sensitivity to multiple transmembrane signaling molecules that
are responsible for detection of an array of endotoxins. Although several eloquent
mutagenesis studies have identified epitopes of CD14 responsible for endotoxin binding
and monoclonal antibodies that competitively bind CD14 developed, no sophisticated
structural studies have been conducted on the protein. The shortcomings of current
treatments of sepsis can be overcome once the structure-function relationships are
determined by NMR spectroscopy. Rational drug design can be accomplished by
identifying high-affinity ligands of CD14 that antagonize the effects of endotoxins by
performing NMR binding studies.
NMR binding studies will resolve the nature of the binding, identifying the
precise residues interacting on CD14 and the binding portions on the endotoxin ligands.
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However, for this to be possible, expression of sufficient quantity of protein is required,
which has been accomplished during the course of this work.
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